Ladies and gentlemen, good day, and welcome to the General Insurance Corporation of India Q1 FY2025 earnings conference call. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Binay Sarda from EY Investor Relations. Thank you, and over to you, sir. Thanks, Mia. Good morning, all participants on the call, and thanks for joining this Q1 FY20 25 earnings call for General Insurance Corporation of India. Please note that we have mailed out the press release to everyone, and you can now see the results on our website as well, it has been uploaded on the stock exchange. In case you have not received the same, you can write to us, and we'll be happy to send it over to you. Before we proceed with the call, let me remind you that the discussion may contain forward-looking statements that may involve known or unknown risks, uncertainties, and other factors. It must be viewed in conjunction with our businesses that could cause future results, performance, or achievement to differ significantly from what is expressed or implied by such forward-looking statements. To take us through the results of this quarter and answer our questions, we have with us the management of GIC, represented by Mr. Ramaswamy, Chairman and Managing Director, and other top members of the management. We'll be starting with the call with a brief quarter gone past, which will then be followed with a Q&A session. I would now like to hand over the call to Mr. Ramaswamy, sir. So over to you. Good morning, everyone, and thank you for joining us in this call. I'm pleased to announce the financial performance for the first quarter ended June 30, 2024. While you would know the past year has been a period of unprecedented challenges for the reinsurance industry, a relentless barrage of catastrophic events had tested our resilience and expertise. Yet, within this turbulent landscape, opportunities have emerged. And at GIC Re, we believe that the essence of the reinsurance business lies in spreading risks and effectively managing our overall portfolio. While we acknowledge the inevitability of catastrophic events, our focus remains on managing these risks prudently. To this end, we have made concerted efforts to de-risk our portfolio by diversifying across various classes of business. This strategy ensures that even if one particular class underperforms, the impact on our overall book is mitigated by the positive performance from other classes. Our continuous focus on rigorous risk assessment and disciplined underwriting practices has resulted in maintaining a healthy combined ratio. This quarter, we achieved a combined ratio of 109.6%, reflecting our commitment to enhancing our operational efficiency and managing risks effectively. Let me now take you through some of the key highlights of the financial performance. The gross premium income of the company was INR 12,405.68 crore for Q1 FY 2025, as compared to INR 8,917.71 crore for Q1 FY 2024. Investment income stood at INR 2,758.99 crore in Q1 FY 2025, as compared to INR 2,559.31 crore in Q1 FY 2024. Incurred claims ratio stood at 89.8% in Q1 FY 2025, as compared to 95.1% during the corresponding quarter of the previous year. Combined ratio in Q1 FY 2025 stood at 109.6% versus 118.47% during the corresponding quarter of the previous year. The adjusted combined ratio, by taking into consideration the policyholder's investment income, works out to 92.97% for Q1 FY 2025, as compared to 95.97% in Q1 FY 2024. Profit before tax stood at INR 1,393.16 crore in Q1 FY 2025, as against INR 935.18 crore in Q1 FY 2024. Profit after tax stood at INR 1,036.36 crores in Q1 FY2025, compared to INR 731.79 crores during the corresponding quarter of the previous year. Solvency ratio stood at 3.36 as on March 31, 2024, as compared to 2.88 as on March 31, 2023. Net worth of the company, without the fair value change account, increased to 38,635.23 crores on March 31, 2024, as against 32,984.27 crores as on March 31, 2023. Net worth of the company, including the fair value change account, increased to 85,926.02 crores on March 31, 2024, as against 69,650.29 crores as on March 31, 2023. On the premium breakup, domestic premium for Q1 FY2025 is INR 10,360.63 crore, and the international book is INR 2,045.04 crore. The percentage split is domestic 84% and international 16%. As you have seen, there is a growth in the domestic premium, while the international book has decreased. It has been our constant endeavor to bring down the combined ratio of our book and enhance our overall performance. We remain optimistic about our future, supported by an improving external environment and our disciplined approach to managing our books. Our broad portfolio diversification continues to position us well for sustained success. As we look ahead, we remain committed to executing our strategy and delivering value to our stakeholders. I also have the pleasure in informing you that since our last meeting, the company has two executive directors now. First one, Mr. Hitesh Joshi, whom you are aware, he was earlier GM in General Insurance, and we are also joined by Ms. Radhika, who was earlier General Manager, United India. GIC hopes to leverage on their experience and knowledge to further our business performances. Having given the highlights, now we will open the floor for questions from interested parties. Thank you. Thank you very much. We will now begin the question and answer session. Anyone who wishes to ask a question, may press star and one on their touchtone telephone. If you wish to remove yourself from the question queue, you may press star and two. Participants are requested to use handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue populates. The first question is from the line of Sanketh Godha from Avendus Spark. Please go ahead. Yeah, thank you for the opportunity. Sir, my first question is on your overseas combined ratio. Last year, you highlighted that you largely provided for the marine exposure, which was old book. And but if you look at the numbers, even today, in the overseas business, in marine line, which is cargo and hull put together, it is more than 500-600%. So still some provisioning with respect to this business is left over, which is still haunting your overseas combined business? That is my first question. Okay. Do you want me to answer now or wait for your rest of the questions? Oh, okay. Second question is on growth, sir. So basically, if I look at the numbers, the health and agri did them meaningfully very well. How to read the numbers? Is it just a recognition change that the crop was written more in the first quarter itself, and that's why you recognized more? Or because last year we wrote around INR 10,000 crore of crop, whether a similar trend will happen, or we have changed the strategy to take more crop exposure in the current quarter and equally whether it is true with the health business. If you can answer these two questions, I have two more, then probably I'll ask. Yeah, sure. So the first question, Sanketh, and thank you for your interest. On the overseas, you know, combined ratio and how marine is still haunting that. Yes, we have made our provisions, but if you see what has happened is effectively the premium has come down. Now, we need to just understand this a bit. This, after all, is a contract that we stopped writing in 2021. But yes, it is long tail, so what has happened is the claims have come later, but premiums have also been coming, though not in the range that, you know, when we were actually writing it. This year, the premium has completely stopped, at least in the first quarter, we've not seen any premium from that particular contract, so which has basically affected marine and motor. If you see the marine and motor, premiums, you would see that it has sunk. Both have sunk and basically the reason is, premium which used to come from that one particular contract that we wrote in the U.S., has completely stopped, at least in the first quarter. And the moment the premium, becomes negative, or the premium growth becomes negative, and, you know, the claims continue at the same range, you would, you would see that the combined would go up. And that is what we are seeing here. I think our provisions with respect to the contract is, is quite good, but we have paid some claims which we have reflected in these accounts. Second, on the growth, well, I would like to, you know, essentially tell you that when you look at the growth this time, it essentially looks like a 40% growth. It's actually not, and I'll tell you why. Last year, around the same time during the first quarter, IRDA changed the estimation policy. Right. Which meant that we really had to adjust our book in the first quarter last year to take care of that. Which meant the first quarter premium last year was quite low compared to what it should have been. Which is why when you look at the premium today that we have shown for the current year, it looks as if we have grown 40% year-on-year. It's really not that; it is just because of the adjustment. And basically, to a great extent, that adjustment was on account of agriculture, where the estimation was slightly higher, which we needed to scale down last year. And that is why you see, as if, you know, agri has grown. It's not really grown much. We continue to remain very cautious in agriculture, and we may possibly end up writing almost the same or maybe slightly more, compared to last year. I don't see a major change there. Health, different story altogether. Health, we have grown, and like I said in my earlier talk also, and maybe I would have talked about this during the May earnings call also, that we really do want to spread our books to ensure that, you know, we also move away from catastrophic business as much as we can. And health has been a good area for us to do. Typically, retail health is something that doesn't come much into the reinsurance market because insurance companies have the wherewithal and the capacity to retain it to themselves. But we managed to get some good retail business this year, which we wrote on first April, and you are seeing a part of that growth in the first quarter as well. So yes, there is growth in health, but I don't think there is as much growth in agri as you thought. It's more an accounting thing because of what we had to do last year. Got it. So, sir, in the follow-up, with respect to the marine thing, so we are taking a hit of almost INR 750 odd crores in the current quarter. So this is almost done away with, I mean, incrementally, we will not see that kind of a pain, and therefore, this 126 come in. Because all other lines have shown a kind of improvement in the overseas business. Only these two have been pain points. So is it fair to assume that now it is done away with and subsequent quarters, we can expect better numbers, assuming no significant CAT losses? Yes, that is what we would love to, love to believe. The way we have provided and the way... I mean, there have been very, detailed discussions with, you know, stakeholders in the U.S., with whom we are dealing in this. But, I'm just hoping that things don't deteriorate further there, because motor, unfortunately, is a bit of a long tail class. We, we strongly believe that we have provided correctly for this, book. Unless things change, dramatically in that market, I think, we can safely say that the worst is behind us. Got it, sir. And the other questions we can have is, is that your international book has declined. This is largely because of motor you discontinuing there or other line of business have done well and that number optically looks weak. That's the case, sir? So basically, yes, the international book has declined because, like I said, the contract that we stopped in 2021, I think, whatever premium was left to come from there, has stopped. At least in this quarter, we have not seen any premium. That's where we are seeing the decrease in the international book. Otherwise, every other business has kind of done the same thing that we did last year. Because honestly, we didn't grow our international book in the current year, typically, which would happen in the first of January of every year. In first January 2024, we didn't grow our book much simply because we still are waiting for our international credit rating to improve. Because only then would we be able to, you know, attract and write good quality business, which we want in our books. Got it, sir. And lastly, two things. One, if you can quantify your domestic cat losses and overseas cat losses in the current year, if there are any, and you indirectly alluded to that point, but when we can hear about your rating change from AM Best? Right. Okay. So, on the catastrophic losses, I don't think we have any significant paid figures currently. But then, yes, there are, there are, you know, provisionings that we have done. So one thing is on the foreign property, in this first quarter, there have been a few events which have been reported. We are still in touch with the, you know, with our business partners in those markets. So basically, to tell you the details, it is, one is the Taiwan earthquake, second is the UAE floods, third is the Brazilian floods, fourth is the German floods, and fifth is the Japan EQ, which has happened recently. Now, these are all very recent events, so we are still, I mean, the initial feedback is the losses are not much, but, you know, in a very prudent way, we have provided for these losses based on the underwriting and the data that we have on our books. Currently, we don't have any paid figures for any of these events. And how much you provided, sir? If you can quantify that number. I can give you two figures. The Taiwan EQ and UAE floods. Yeah. Taiwan is INR 73.68 crores and UAE floods is INR 50.38 crores. Okay. Perfect. Anything provided. Anything on domestic, sir? So domestic, nothing major, but what we have done is, in some of the cat events that we had last year, if you remember, I talked about five major cat events which had hit us, last year, out of the nine cat events that we had. So some of them, we have slightly, you know, increased the, provisioning. So that is it. I mean, so domestic is decently okay compared to, foreign currently. On the cat front, but, you know, basically these next two quarters would be where we would expect some losses to come in from catastrophic. We are, of course, very carefully monitoring events that are happening across the country. Nothing negative applies from Sikkim, sir, right? Not yet. Not yet. Not yet. Okay. And if you can finally comment on that rating change thing, that's it from my side. So, what has happened is, typically, the procedure followed is once our year-end closing is done and, you know, our numbers are revealed, we send all the data over to the rating agency, where they can study the numbers, you know, go through their models and understand how we are performing. And after that, they come to us on a personal visit to understand the qualitative matters. So that happened on the June 12 of July this year. So we have met them, we have given them all the details that they wanted. And of course, now, as and when they ask us for, you know, incremental data, that is being provided to them. And we are hoping that they will come back to us with our rating. What we have requested—so last year, if you remember, the rating happened in the month of November, actually... So So what we have required, and there we got a double jump, double boost, compared to our earlier ratings. So what we have requested this, them this time is to, you know, hopefully give the—give us our rating by, you know, September, September end, so that that gives us, you know, two or three months where we can then work with our business partners and, you know, speak to them about, writing better businesses and more businesses from there. This is, of course, under the assumption that, you know, we would get a rating push, this year. We are in touch with AM Best on that and, you know, we're also in touch with some of our business partners with whom we used to write quite a good amount of business, so that we can tap into that business which is waiting. Got it. Perfect. That's it for my shift. Thank you. Thanks. Thanks, Sanket. Thank you. Ladies and gentlemen, you may press star and one to ask a question. The next question is from the line of Aditi Joshi from JP Morgan. Please go ahead. Yeah, good morning, sir, and thank you for taking my question. So I have a couple of questions. So just following up on this gross comment that you made that the growth looks high because of the changes last year. But I'm just wondering that those changes they do not apply this year, because if so, it will be applied this year, then probably the growth looks high. The second is that can you please comment on the April renewal cycle, as in, in terms of the reinsurance pricing trend, in various segments such as health, motor, or even crop? Have you seen any insurance pricing hike in this renewal? Also, what is your outlook of the pricing trend for the rest of the year and the next year? This is one question. Just on the health side, you mentioned that you would like to focus and you are focusing on the retail side of the business. But if we look at the jump in the premiums in the health insurance, it looks quite a lot. So I'm just wondering what is causing that jump? Is it also some portion of that growth is coming from the group side as well? And also, just on the health insurance underwriting, the primary insurance non-life insurers have reported somewhat elevated claims. So how is your experience in the health insurance health reinsurance underwriting? Yeah, these are my questions. Thank you. Okay, I was not quite able to understand your first question, but what I will do is I'll take the other two. So, you wanted to know about the pricing outlook on the first April renewals. So, the pricing was flat. I mean, so if you're talking of the reinsurance pricing, that was pretty flat across whether it was property or other classes. That is on the reinsurance pricing, typically the kind of non-prop pricing that we talk about. So basically, again, what happens is India is predominantly a proportional market where we support insurance companies proportionally. So obviously, a great deal of, you know, our time is taken up in trying to understand how, you know, the insurance market is performing. So the certain things that I would like to bring out here is, so while on the first April renewal time, line, the pricing was quite firm on the insurance side, but I think in this last one quarter, the April to June quarter, we are seeing a situation where, at least in, property and maybe in group health, we are seeing, quite a challenge in the pricing on the direct side. So insurance companies are, being very, very competitive on the pricing. And so obviously that is a matter of concern for us, and, we are interacting with the companies and looking at the situation very carefully. So that is on the pricing. Whether this pricing will remain like this on the direct side is something that we need to see. Like I said, all reinsurers are concerned about the way the pricing is going, and we are in touch with our business partners to ensure that, you know, the viability of the market is maintained. Second, on the health side, you said it looked as if a major part of our growth is coming from group. No, it's not. Let me also be very candid here in saying that the business that we wrote on 1st April on health a major growth that we did was basically on retail health. So the treaty that we wrote on 1st April are something that look at retail health and not group. We don't have a great appetite for writing group health simply because of the way pricing happens there, about the way how competitive it is, and so we're not very comfortable with that business. Like I said earlier, also, Sanket, normally, retail reinsurance is, I mean, retail health is something that doesn't come into the reinsurance market simply because, you know, it is small ticket business, most companies are able to retain it. But then, sometimes what happens is companies do look for reinsurance treaties to augment their capital to ensure that, you know, they are able to manage their capital better. So we've been able to spot a few opportunities in this and, you know, we've been able to write those treaties, and we're quite happy with that. You talked about increased levels of claims happening, which is fine. So you know, the way we create these treaties is where there is a combination of claims ratios and expense ratios adding up to a certain level. So even if the claims go up slightly, it gets adjusted with the acquisition cost. So I think we are pretty comfortable in that business. Like I said, this is something that we've been targeting to do to ensure that, A, we get the chance to you know, diversify our book, and B, we are able to you know, look at profitable growth as well. So these are the two points I got from you, Aditi. If there is another question that I'm missing, please ask me again. Yeah, so, on the crop side, firstly, can you... I'm sorry, but can you please explain very briefly what was the changes in the accounting, probably which happened last year? And this is one. And the second, just following upon the growth, so as you mentioned that retail health does not come to insure very easily. So, what is your outlook on the growth of this business line for the rest of the year? Okay. So, I'll take the retail health first. So yes, so the point is, it is a treaty that we have written, which encompasses business that, you know, the insurance company would write across the year. It's a treaty that looks at retail health businesses written by a particular cedent, you know, throughout the year. So we do expect this growth to happen through the year. What will happen next year is something that we will look to before the renewals next year. Coming to agriculture, I'll just give you a brief. So you wanted to know what is the accounting thing? Basically, like I said earlier as well, last year, around this time when, you know, IRDA came out with very clear instructions as to how we should be estimating our premium. Obviously, we had to change the way we were doing from the earlier times. So that obviously caused the premium to come down last quarter, that is the quarter of the last year. So which is why when you look at it with this year, it actually looks as if the growth is substantial, which is not. I'll ask my DGM accounts to just give you the brief on this. Rajesh, Rajesh. Hi. Good morning. This is mainly because of the estimation policy changes. So IRDA has asked us to estimate only one quarter, which is the current quarter in which accounts are happening. But in case of agriculture, we do not get accounts for the one or previous one or two year also. So those figures we used to estimate till March 31, 2023. In 2023, we have removed those estimations. That's why the premium, gross premium, has gone down sharply. Around INR 1,000 crore premium has gone down because of the changes in estimation policy. That's why it was looking very low in 2023. Comparative figure, you can take it as INR 1,618 crore, then this growth will not be that sharp as it's looking currently. Yeah. And so those changes in estimation policy will not apply in this quarter of one such quarter, 2025? No, we are already doing that. So what happened last year was, you know, like Rajesh explained, earlier years or earlier quarters, estimation was also carried forward. Wherever we didn't get any premium for, you know, businesses that we were doing, we had estimated that in our books. But then IRDA said, "You can now estimate only for this quarter." So what we have done this quarter is we are estimating only for this quarter. What we did for the quarter ending 31st March 2024, we estimated only for that one quarter. So that is something that is carried forward, so you will not see any difference now. But when you look at 30th June 2023, obviously the first quarter in which this change was done, obviously there was a, you know, huge change in the way, the estimation was done. Which is why 36, 23 showed a sharply lower premium compared to what it should have been. Which is why I gave that, you know, message earlier that maybe you shouldn't look at this as actually a 40% growth. It is not. I still maintain that this would be closer to about 15, 16% growth quarter-on-quarter. Sure, thank you. Thanks, Aditi. Thank you. Ladies and gentlemen, you may press star and one to ask a question. The next question is from the line of Jenish Shah, an individual investor. Please go ahead. Yeah, thank you, sir, for giving me this opportunity. I have a few questions around the domestic premium market. Basically, you just alluded that, leaving apart the regulatory changes which were enforced in the last year, on a comparable basis, the domestic premium or the premium growth for the quarter is 15%-16%. And this happened in spite of the international premium going down. If you can give a little bit more clarity onto how the business domestically has grown on a like-to-like basis, on a comparable basis, that will be helpful. And second, there are few... In the last quarter, I think there was few guidances or, few directions which the company has given. That is, it expects to grow 15%-16% in the business, in the current year… and also expect the combined ratios to be more closer to 105%-106%. Given the current situation, and I know it's been hard work which you, you've done in last few years, do we think the fruits of that is likely to come through, in this year onwards or, or I mean, saying which, from any particular time when you expect this to change? I know there is an event which you are expecting for the rating upgrade, but, I mean, if you can just take us through that journey as to how do we look, the journey for next year and half or couple of years, that will be helpful. Thank you, sir. Yeah. Thanks, Jamie. So, come to your first question. Like you brought out, after our financial year 2024 finalization in May, I had given a guidance that we would typically be growing at around 15, 16% for the year. I think that guidance remains. Whatever growth we are seeing is more or less in that. And that guidance had taken into account the fact that, you know, the domestic premium or the international premium could go down because of some premium not coming from earlier contracts. So I think we are more or less on track with overall growth of about 15%, you know, for the year. Obviously, the growth will come from domestic this year. It will not come from international because, assuming that, you know, we get our rating upgrade as well, what would happen is the business that we plan to write would start from first of January. Even if we are able to write a decent increase in premium on first of January, it would really, really not reflect too much in our books. Because that will come into our books, there is normally a lag of at least six months before it hits our books. You would possibly see that happening only in the next financial year. Which is why, this year, I think whatever increase we are talking about would come from the domestic market. The domestic international skew will be higher. We are already seeing that for the quarter, it is 84% domestic and 16%, international. It may become slightly better than that. But if you see, that was one reason why we wanted to diversify our book within India as well. The reason to go into health retail was also that. Because as a reinsurer, we normally look to diversify our books so that one particular event should not have any material impact on our overall performance. So when we realized that we may not be able to get the kind of diversification in geography, we have done that diversification in class of business. So rather than writing more in property, we are now writing in health. So there is now diversification. If you see our bigger books, it is typically property, it is, motor, of course, being in this market. Health is a major, now class for us, and of course, agriculture also comes in somewhere there. So we are trying to diversify ourselves, within the market so that, you know, overall our performance can be better. So, I think the guidance from our side, continues, you know, whatever we did tell you, in the last earnings call. Because honestly, in this one quarter, nothing much has changed. I think to a great extent, we will wait for the next two quarters to tell us very clearly, you know, how the book is looking and how the business is shaping up. Because, these are the next two quarters where you would expect to see some catastrophic losses coming by or, you know, if the rating goes up, then we would also look to write some business on first January, which would give some, you know, different flavor to, what we expect to do. Over the next couple of years, which is what we wanted, maybe two years or even three years, we would expect to grow our book reasonably, not necessarily only in domestic. Like I said, in case we get our rating upgrade, we would also start growing, internationally. But the idea would be to write businesses in such a way that our profitability is not impacted. In fact, our combined ratio should keep coming down. and that we see happening, hopefully without any, you know, a very negative kind of cat happening. I think we should be able to manage that going forward. In the next 2-3 years, yes, we would expect to bring our combined close to 105-106. So this year, you think the combined ratio will be flat, or it will be showing any improvement? It might be flat. We hope it will come with an improvement, because I need to explain a bit here. Because the moment you grow your book, typically in a reinsurance business, what would happen is, in the first year, there could always be a strain on the combined, and there is a reason behind that. It depends on the kind of business that you're writing. It depends on the kind of book that you're writing. If you are writing a predominantly a proportional book, like what we are writing today, and you grow your book, what would happen is, typically the reinsurance accounting is such that you would earn or you would recognize only 50% of the premium, right? And supposing you are writing a profitable book and, you know, the loss ratio is, say, 55% or thereabout, then you would typically, what would happen is you would typically end up paying about 40% as acquisition cost, assuming that you write a book, you know, you write a treaty at 5% profit.... Now, the problem with that is, you are actually writing a profitable book, but the commission of 40% which you have to pay is paid upfront, right? So after that, even if assuming you book INR 20 of loss as well, the problem is this: you have got a gross premium increase of INR 100, on which you earn only 50. You have already paid out 40 as commission. You book 20 as claims. On a good, profitable book of business on year one, you still would be at INR 60 vis-a-vis INR 50 of earning, so your combined is 120. I'm just giving you an example. So this is the way a reinsurance book would evolve. So when you grow, like we have grown this time, you know, after three or four years of continuous degrowth, of weeding out unprofitable businesses and making the portfolio strong, the day you decide to grow, that first year there could be, I'm saying there could be chances that your combined could worsen or remain flat. Simply because, you know, the earning doesn't happen 100%, the earning is only 50% of the increased book that you're writing. Now, if it were more non-proportional, then it is fine, because in non-proportional, the commissions or the cost that you pay out is only about 10%-15%, so you still have scope there. So we need to really study our book and understand how losses would be booked in the year, and then take a call. But I would say that we would more or less remain flat as far as combined is concerned. Okay, thank you. And maybe one more on a macro. Generally, I think if we look at the major change on the macro environment, which happened post-2022, was an increase in the interest rates and the capital shortages were seen in the industry on a global basis. Now that the trend is likely to change, probably the interest rates are likely to ease over the next one year or so, how do we see the business shaping up, or basically, the competition, do you think is going to heat up, that will have an impact on the margins? How is your expectation on the business environment, which is likely to evolve in an interest rate raising environment? Thank you. Though, and that I'm talking about the U.S. environment, I mean, basically the global interest rate environment. Thank you. Yeah, I mean, we do appreciate that. Again, you know, globally, the way I see it, you know, couple of years, pricing has been quite good, I would say, on the reinsurance front. Losses have been reasonably, comfortable, so obviously there is always a pressure, to bring down pricing. So obviously, you know, more capacity is coming into the market and obviously that adding a, competitive, pressure on pricing. So globally, yes, I would expect that. But India is slightly different, and again, I'm talking about India simply because, you know, a major part of our book is here, so obviously what happens here affects us, much, much bigger way. Here, I would say that, you know, while the way we are looking at the interest rates could be easing, but we feel that it might remain constant this year and maybe going forward in the next year, it could ease. The point is, I guess, to a great extent, it will be more regulatory interventions which could drive things here. So we are looking at two possible drivers. One is, of course, IFRS, and second is, more importantly, RBC, which is risk-based capital. Now, we believe, again, you know, there's a lot of things that are based on assumptions here. So we believe that, you know, if RBC were to be implemented in this market, looking at the way pricing is happening, and, you know, obviously, risk-based capital, you don't look at a very simple, simplistic way of determining solvency. You look at exposures and how it is priced and, you know, how it would affect your book. And with that thing in mind, I think quite a few companies would be strapped for capital, may not have a very good solvency ratio going forward. In such a situation, you know, we believe that gives us opportunities to support, shall I say, better underwriting companies who need maybe some temporary reinsurance support. I think we should be in a good position to manage that and, you know, do well for ourselves. But like I said, it all depends on when these things happen and, you know, how the market takes it. So, I think we are quite sanguine about, you know, the way, the market is moving. I think more than anything else, we are worried about how it is getting priced and how, you know, insurance companies are looking at the whole thing. Thank you, sir. Thank you very much for this elaborated explanations. Thank you. Thanks, Jimmy. Thank you. The next question from the line of Ritika from Bandhan Mutual Fund. Please go ahead. Thank you, sir. So firstly, if you could just reiterate the point that you were mentioning for the previous person's question, that you think that RBC would actually lead to better opportunities for growth for you. Because what we understood that when we spoke to, obviously, we speak to limited listed players who think that actually capital there would be better off in the RBC regime. So that's the first question. And the second, sir, just while obviously you are a good representative of the overall market, but given that PSU general insurers are also still a reasonable share of the market. You know, certain media articles suggest that, you know, they have been asked to be very careful of the incremental business or I don't know, on the health side and on the motor side, to actually write the lower businesses which are loss-making for them. So how does that impact you? That's the second question. Right. On the first question, Ritika, I think, you know, I mean, there are different views, different ways people are looking at it. And like I said, it all depends once we understand from the regulator how they are planning to implement risk-based capital. GIC has a lot of experience in handling RBC, so we have branches and subsidiaries, subsidiary companies across the world, where, you know, Solvency II is implemented. So we understand how these things work. We understand how what is looked at, what factors are looked at, while determining solvency in a risk-based capital environment. So we believe that, and again, so like I said earlier, there are assumptions here, and our assumptions is based on the way pricing is done in this market, the way people take on board, liabilities. Today, it's a very simple solvency, factor-based, solvency, where if you have a profitable book, your capital works well for you. But we believe that once, it is based on the exposures taken on board and whether those exposures are, you know, limited to a particular geography or is it well spread out, we believe that some of the companies could be stuck for capital, and that is where we look to provide reinsurance solutions to these companies, and that is where we look at opportunities. Second, you talked about, the advisory from the DFS to the insurance companies. Well, that's honestly, it is meant for the four insurance companies. It has nothing to do with GIC. I guess to a great extent, again, now, I may not have 100% knowledge on this, but maybe to a great extent, the health portfolio that the insurance company, PSU insurance companies are writing may not be profitable, and which is why this advisory is given. Our share of health business from the PSUs are very less, simply because, you know, these are big companies. They have very good capacities and, you know, so they don't take much of reinsurance. Where they would look for reinsurance is on the group health or the government health schemes. That is something which comes on a facultative basis, and GIC does not have much of a appetite for these kind of businesses because we feel that, you know, normally these end up being not well priced, and so it doesn't really fit into our appetite. Their writing or not writing that business would have no impact on our business at all. So just one clarification. I'm sorry if I didn't get you correctly. To the, the question, to the RBC comment, you were mentioning, your competitiveness as a reinsurer increases versus other reinsurer? Are you or were you saying that the other GI players might have a issue, and that's how you would look to maybe, support more? I'm sorry, I, I, I just wanted that clarification. Yeah. Yes, yes, indeed. So we feel that some of the GI players, I'm talking of the insurance players here, they might find themselves in a bit of difficulty in terms of capital because of the business that they are writing and where they are writing and how they are writing and how it is priced and all that stuff. So we believe that in the short term, we could actually have some advantages there in writing certain businesses which we may otherwise not see in the market at all. All right. So that's, that's very useful. Thank you so much. Thank you. Thank you. Ladies and gentlemen, you may press star and one to ask a question. The next follow-up question is from the line of Aditi Joshi from JP Morgan. Please go ahead. Thank you for the opportunity again. Yeah, I have a couple of quick questions. So, on this acquisition costs that we have mentioned, that in the first year we have a significant acquisition cost putting. So when we adopt this IFRS standard, in which the acquisition costs are likely to be deferred over a period of the contract, so, how much of the impact from the deferment of acquisition cost and from the other sectors as well, On a combined basis, how much of the, let's say, improvement in the combined ratio we can expect under the IFRS accounting? And the second one is on the reinsurance distribution and broking segment. I know a couple of new distributors are entering into the reinsurance space. So I just wanted to understand the impact for you as in, does it give you a significant growth opportunity for you, or how are you looking at it from a distribution perspective? Yeah, that's it. Thank you so much. Did you talk about reinsurance brokers entering the field? Yeah, yeah. Reinsurance brokers, yeah. Okay. All right. All right. So, on the IFRS, we are still studying, Aditi, but I'll ask Rajesh to explain to you what our understanding is. But as I said, we are still in talks with our partner to understand, you know, how this entire thing will work. Rajesh? Hi, good morning. You are right, basically, so like, we are doing the earning for the premium, in IFRS we'll be doing the earning for the deferred commission expenses will be deferred, so that benefit will be there in IFRS. But, as I told you that, we are still getting knowledge from the partners and how it will impact actually, that will come in- we'll be knowing later on. But yes, that in the commission will be deferred, like in premium we are, we are earning, unearned premium we are providing. So yeah, I hope that, you know, I guess going forward, we'll be able to, you know, address that further, but that is the initial understanding. On the reinsurance brokers coming in, we welcome them, Aditi, because honestly, we deal and we do business with all the brokers in this market. We have no problems there. As long as they are able to show us business that is to our appetite, that is priced well, that is managed well, and that the loss ratios, you know, we can, we can see that loss ratios can be, you know, kept within a certain range. I think we're more than happy. So, if the, if the arrival of these reinsurance intermediaries broaden the market and bring more business into the market, more than happy to work with them. I got it. Thank you so much. Thank you. Ladies and gentlemen, you may press star and one to ask a question. A reminder to all the participants, you may press star and one to ask a question. As there are no further questions from the participants, I now hand the conference over to the management for closing comments. Thank you, everyone, for all the support, for the way you've been following our company and, you know, all your questions, because honestly, it helps us to think differently, understand your viewpoints as investors and analysts, and, you know, allows us to take corrective action as and when required. Like I said earlier as well, we are committed to ensuring that, you know, we make our portfolio much more stable, less prone to losses or, you know, sudden spurts in losses. Ensure that there is diversification across the board to ensure that, you know, the returns to the stakeholders is meaningful. Thank you once again for all the support, and I know that Monday morning, it's quite difficult to find time. Thank you that you are here, and wish you a great week ahead. Thank you. On behalf of General Insurance Corporation of India, that concludes this conference. Thank you for joining us, and you may now disconnect your lines. Thank you.